Allakos (NASDAQ:ALLK) released its quarterly earnings results on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.10), Fidelity Earnings reports.

ALLK opened at $53.17 on Friday. Allakos has a 1 year low of $26.00 and a 1 year high of $58.52.

Several research firms recently issued reports on ALLK. Goldman Sachs Group began coverage on Allakos in a research note on Monday, August 13th. They issued a “neutral” rating and a $31.00 price target for the company. Jefferies Financial Group began coverage on Allakos in a research note on Monday, August 13th. They issued a “buy” rating and a $53.00 price target for the company. William Blair began coverage on Allakos in a research note on Monday, August 13th. They issued an “outperform” rating for the company. Finally, Zacks Investment Research downgraded Allakos from a “buy” rating to a “hold” rating in a research note on Tuesday.

COPYRIGHT VIOLATION NOTICE: “Allakos (ALLK) Issues Quarterly Earnings Results, Misses Expectations By $0.10 EPS” was first posted by Daily Political and is owned by of Daily Political. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.dailypolitical.com/2018/11/10/allakos-allk-issues-quarterly-earnings-results-misses-expectations-by-0-10-eps.html.

Allakos Company Profile

Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

Read More: How Important is Technical Analysis of Stocks

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.